Philips Expands Availability of LumiGuide Light-Based 3D Navigation in Europe and the US
Philips has extended commercial availability of its LumiGuide 3D Device Guidance system across Europe and the United States, marking a significant step in the adoption of light-based navigation for image-guided therapy. Announced at RSNA 2025, the rollout brings the world’s first real-time AI-enabled 3D visualization technology powered by light—rather than continuous X-ray—to a wider clinical audience. The company positions this expansion as part of its broader effort to improve radiation safety in interventional procedures.
LumiGuide is built on Philips’ Fiber Optic RealShape technology, which uses light reflected through an optical fiber to generate real-time, full-color 3D views of guidewires and compatible catheters inside the body. This approach allows clinicians to navigate complex vasculature without relying on fluoroscopy. Philips reports that the technology can shorten aortic repair procedures and significantly reduce radiation exposure. Adam W. Beck, MD, of the University of Alabama at Birmingham, said, “I have done over 160 fenestrated and branched aortic procedures with LumiGuide and have found that the system improves efficiency, reduces the procedure time, and reduces time on the fluoroscopy pedal to near zero.”
Integrated directly into the company’s Azurion image-guided therapy platform, LumiGuide adds to a growing set of AI-enabled tools designed to enhance real-time guidance and procedural workflow. Philips executives said the platform’s global footprint and existing clinical adoption help support broader implementation. “Moving LumiGuide from limited to full commercial availability is an important milestone in expanding access to advanced image-guided therapy,” noted Stacey Beske, who leads Philips’ Image-Guided Therapy Devices business. Atul Gupta, MD, Chief Medical Officer for Diagnosis & Treatment, added that expanding access will help teams “treat complex vascular disease with precision and safety, while reducing radiation risk for patients and teams in the lab.”
The system has already been used in more than 2,000 procedures since its limited release in 2023. Full commercial availability is expected to begin in January 2026 in key European markets and the United States. Philips plans to continue generating clinical evidence to support everyday use and refine its application across different vascular interventions.
LumiGuide also aligns with a broader Philips strategy focused on reducing radiation exposure through innovations such as ClarityIQ, DoseAware, and Echonavigator, as well as clinical studies like the RADIQAL trial. By advancing light-based navigation and integrating it with established imaging platforms, Philips aims to support safer, more efficient endovascular procedures and expand the role of minimally invasive therapy worldwide.
